BR9807627A - Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. - Google Patents
Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.Info
- Publication number
- BR9807627A BR9807627A BR9807627-2A BR9807627A BR9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- analogue
- preparation containing
- preparation
- preparing
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 8
- 108010074860 Factor Xa Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 3
- 108020004511 Recombinant DNA Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 108010014173 Factor X Proteins 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"ANáLOGO DE FATOR X, DNA RECOMBINANTE CODIFICANTE PARA UM ANáLOGO DE FATOR X, PREPARAçãO CONTENDO UM ANáLOGO DE FATOR X PURIFICADO OU UMA SUA PROTEìNA PRECURSORA, PREPARAçãO CONTENDO ANáLOGO DE FATOR XA APRESENTANDO ALTA ESTABILIDDE E INTEGRIDADE ESTRUTURAL, USOS DE UMA PREPARAçãO E DE UM áCIDO NUCLEICO, E, PROCESSOS PARA A PREPARAçãO DE UM PREPARADO CONTENDO ANáLOGO DE FATOR X RECOMBINANTE PURIFICADO, E PARA SE PREPARAR UM PREPARADO CONTENDO FATOR XA OU ANáLOGO DE FATOR XA ATIVOS". A invenção refere-se a análogos de Fator X que têm uma modificação na área do sítio de clivagem de ativação de Fator Xa naturalmente ocorrente, sendo que a referida modificação representa um sítio de processamento de uma protease que não cliva naturalmente nesta área da seq³ência do Fator X. A invenção também refere-se a preparações contendo os inéditos análogos de Fator X e a processos para sua produção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0033597A AT405516B (de) | 1997-02-27 | 1997-02-27 | Faktor x-analoge mit modifizierter proteasespaltstelle |
PCT/AT1998/000045 WO1998038317A1 (de) | 1997-02-27 | 1998-02-27 | Faktor x-analoge mit modifizierter proteasespaltstelle |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9807627A true BR9807627A (pt) | 2000-02-22 |
Family
ID=3487868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9807627-2A BR9807627A (pt) | 1997-02-27 | 1998-02-27 | Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US6573071B1 (pt) |
EP (1) | EP0966536B1 (pt) |
JP (1) | JP4317976B2 (pt) |
AR (1) | AR012034A1 (pt) |
AT (2) | AT405516B (pt) |
AU (1) | AU744428B2 (pt) |
BR (1) | BR9807627A (pt) |
CA (1) | CA2282707A1 (pt) |
CZ (1) | CZ298298B6 (pt) |
DE (1) | DE59813518D1 (pt) |
ES (1) | ES2263199T3 (pt) |
HU (1) | HU225246B1 (pt) |
IL (2) | IL131346A0 (pt) |
NO (1) | NO327878B1 (pt) |
PL (1) | PL190734B1 (pt) |
SK (1) | SK286359B6 (pt) |
WO (1) | WO1998038317A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT405517B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
AT410216B (de) * | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
US7223577B2 (en) * | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
FR2841904B1 (fr) * | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
US20040132156A1 (en) * | 2002-10-04 | 2004-07-08 | Schering Aktiengesellschaft | Modified hepsin molecules having a substitute activation sequence and uses thereof |
AU2005274406B2 (en) * | 2004-08-17 | 2010-07-01 | Csl Behring Gmbh | Modified vitamin K dependent polypeptides |
EP1728798A1 (en) * | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
ATE548380T1 (de) | 2006-04-20 | 2012-03-15 | Kringle Pharma Inc | Mutante des hgf-precursor-proteins und aktivierte form davon |
GB0710321D0 (en) * | 2007-05-30 | 2007-07-11 | Nhs Blood & Transplant | Method |
US9956272B2 (en) | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
AU2008287340A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
CN101802188B (zh) | 2007-09-28 | 2013-08-21 | 普托拉制药有限公司 | 用于因子Xa抑制剂的解毒剂和其使用方法 |
NZ592837A (en) | 2008-11-14 | 2012-10-26 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8673860B2 (en) | 2009-02-03 | 2014-03-18 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
PT2414517T (pt) | 2009-03-30 | 2016-12-27 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
NZ596778A (en) | 2009-06-08 | 2013-11-29 | Amunix Operating Inc | Glucose-regulating polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
EP2453910B1 (en) | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
CA2850603C (en) * | 2011-09-30 | 2021-11-16 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
SG10201606783RA (en) | 2012-02-15 | 2016-10-28 | Amunix Operating Inc | Factor viii compositions and methods of making and using same |
BR112014019901A8 (pt) | 2012-02-15 | 2018-01-02 | Biogen Idec Inc | Proteínas de fator viii recombinante |
CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
GB201211617D0 (en) * | 2012-06-29 | 2012-08-15 | Univ Aberdeen | Production of cyclic peptides |
AU2013293573B2 (en) | 2012-07-25 | 2016-10-27 | Catalyst Biosciences, Inc. | Modified Factor X polypeptides and uses thereof |
MX2015008813A (es) | 2013-01-31 | 2016-03-31 | Pfizer | Composiciones y metodos para contrarrestar la inhibicion del factor xa. |
FR3001729B1 (fr) * | 2013-02-04 | 2015-03-06 | Lab Francais Du Fractionnement | Mutants du facteur x |
CN105008530A (zh) * | 2013-03-12 | 2015-10-28 | 诺和诺德股份有限公司 | 凝血酶敏感性凝固因子x分子 |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
CN112195169A (zh) | 2013-09-24 | 2021-01-08 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
RU2585532C2 (ru) * | 2014-01-31 | 2016-05-27 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) | Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора |
WO2016028872A2 (en) | 2014-08-19 | 2016-02-25 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor ix function |
CN108472337B (zh) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | 因子ix融合蛋白以及其制备和使用方法 |
KR20180038560A (ko) | 2015-08-28 | 2018-04-16 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법 |
IL308416A (en) | 2016-12-02 | 2024-01-01 | Bioverativ Therapeutics Inc | Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors |
SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
KR102613936B1 (ko) * | 2020-11-13 | 2023-12-15 | 한국생명공학연구원 | 자가분해능이 저하된 켁신 효소 및 이의 생산 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT366916B (de) | 1980-04-02 | 1982-05-25 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen |
US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
AT382783B (de) | 1985-06-20 | 1987-04-10 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
JP4236698B2 (ja) | 1990-11-26 | 2009-03-11 | ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー | 宿主細胞でのpaceの発現およびその使用法 |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
DE4325872C1 (de) | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
AT404838B (de) | 1995-11-24 | 1999-03-25 | Immuno Ag | Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen |
AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
-
1997
- 1997-02-27 AT AT0033597A patent/AT405516B/de not_active IP Right Cessation
-
1998
- 1998-02-25 AR ARP980100832A patent/AR012034A1/es not_active Application Discontinuation
- 1998-02-27 IL IL13134698A patent/IL131346A0/xx active IP Right Grant
- 1998-02-27 PL PL98335382A patent/PL190734B1/pl not_active IP Right Cessation
- 1998-02-27 HU HU0100652A patent/HU225246B1/hu not_active IP Right Cessation
- 1998-02-27 SK SK1171-99A patent/SK286359B6/sk not_active IP Right Cessation
- 1998-02-27 EP EP98903943A patent/EP0966536B1/de not_active Expired - Lifetime
- 1998-02-27 AT AT98903943T patent/ATE324454T1/de active
- 1998-02-27 US US09/367,791 patent/US6573071B1/en not_active Expired - Lifetime
- 1998-02-27 WO PCT/AT1998/000045 patent/WO1998038317A1/de active IP Right Grant
- 1998-02-27 AU AU62002/98A patent/AU744428B2/en not_active Ceased
- 1998-02-27 CZ CZ0303299A patent/CZ298298B6/cs not_active IP Right Cessation
- 1998-02-27 ES ES98903943T patent/ES2263199T3/es not_active Expired - Lifetime
- 1998-02-27 DE DE59813518T patent/DE59813518D1/de not_active Expired - Lifetime
- 1998-02-27 CA CA002282707A patent/CA2282707A1/en not_active Abandoned
- 1998-02-27 BR BR9807627-2A patent/BR9807627A/pt not_active IP Right Cessation
- 1998-02-27 JP JP53706298A patent/JP4317976B2/ja not_active Expired - Lifetime
-
1999
- 1999-08-10 IL IL131346A patent/IL131346A/en not_active IP Right Cessation
- 1999-08-26 NO NO19994139A patent/NO327878B1/no not_active IP Right Cessation
-
2003
- 2003-04-04 US US10/407,123 patent/US7220569B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NO994139D0 (no) | 1999-08-26 |
IL131346A0 (en) | 2001-01-28 |
CA2282707A1 (en) | 1998-09-03 |
EP0966536B1 (de) | 2006-04-26 |
WO1998038317A1 (de) | 1998-09-03 |
NO994139L (no) | 1999-10-27 |
ATE324454T1 (de) | 2006-05-15 |
US6573071B1 (en) | 2003-06-03 |
DE59813518D1 (de) | 2006-06-01 |
PL335382A1 (en) | 2000-04-25 |
HU225246B1 (en) | 2006-08-28 |
AU744428B2 (en) | 2002-02-21 |
US20030181381A1 (en) | 2003-09-25 |
PL190734B1 (pl) | 2005-12-30 |
NO327878B1 (no) | 2009-10-12 |
AU6200298A (en) | 1998-09-18 |
SK286359B6 (sk) | 2008-08-05 |
CZ303299A3 (cs) | 2000-02-16 |
HUP0100652A3 (en) | 2003-01-28 |
IL131346A (en) | 2007-05-15 |
CZ298298B6 (cs) | 2007-08-22 |
ATA33597A (de) | 1999-01-15 |
EP0966536A1 (de) | 1999-12-29 |
JP4317976B2 (ja) | 2009-08-19 |
HUP0100652A1 (hu) | 2001-06-28 |
SK117199A3 (en) | 2000-05-16 |
AT405516B (de) | 1999-09-27 |
JP2001513631A (ja) | 2001-09-04 |
AR012034A1 (es) | 2000-09-27 |
ES2263199T3 (es) | 2006-12-01 |
US7220569B2 (en) | 2007-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9807627A (pt) | Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. | |
Nutt et al. | The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure. | |
RU95115239A (ru) | Аналог эритропоэтина | |
HUP9902698A2 (hu) | Humán bikunin | |
BR9807618A (pt) | Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa. | |
Grant et al. | Biosynthesis of an insulin precursor by islet tissue of cod (Gadus callarias) | |
PT91099A (pt) | Processo de preparacao de peptidos de ligacao a proteases de retroviros, dos seus intermediarios e de composicoes farmaceuticas | |
DK471085D0 (da) | Farmaceutiske sammensaetninger indeholdende syntetiske phospholipiderog et farmaceutisk aktivt stof samt deres fremstilling og anvendelse | |
PT81168B (pt) | Processo para a preparacao de proteinas inibidoras da coagulacao do sangue e de composicoes farmaceuticas contendo estas substancias | |
HUP9800075A2 (hu) | Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk | |
ES2028796T3 (es) | Procedimiento para producir preparados farmaceuticos que contienen interferon alfa. | |
ATE84048T1 (de) | Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung. | |
JPS6485096A (en) | Hybrid human protein c and biotechnological synthesis thereof | |
PT81991B (pt) | Processo para a preparacao de derivados peptidicos, analogos a pepestatina, inibidores darenina e das proteases acidas | |
BR9710615A (pt) | Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea. | |
BR9803960A (pt) | Gene de desidrogenase de d-sorbitol. | |
US5397694A (en) | Protease inhibitor | |
Tam et al. | The importance of disulfide bridges in human endopeptidase (enkephalinase) after proteolytic cleavage | |
PT81345B (pt) | Processo para a preparacao de novos peptideos activos sobre o sistema nervoso central com accao sobre o sistema colinergico, e de composicoes farmaceuticas contendo estes compostos | |
EP0210279A4 (en) | Stabilized human prourokinase. | |
ATE111525T1 (de) | Plasminogenaktivator-varianten und verfahren zu ihrer herstellung. | |
EP0195680A3 (en) | The synthesis of protein with an identification peptide | |
ES2080060T3 (es) | Proteinas que tienen actividad de union a interferon-gamma. | |
PT704527E (pt) | Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina | |
IT1222427B (it) | Procedimento per la purificazione di interferone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A, 6A,7A,8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1887 DE 06/03/2007. |